GeneReach Biotechnology (ROCO:4171) NonCurrent Deferred Liabilities: NT$0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4171 GeneReach Biotechnology Corp ROCO:4171
52 GF Score
Price NT$17.20
GF Value NT$24.55
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is GeneReach Biotechnology NonCurrent Deferred Liabilities?

GeneReach Biotechnology ROCO:4171 -0.29% 52 NonCurrent Deferred Liabilities is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:4171 with a GF Score™ of 52/100 and a GF Value™ of NT$24.55 (Possible Value Trap). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GeneReach Biotechnology's non-current deferred liabilities for the quarter that ended in Mar. 2026 was NT$0.0 Mil.

GeneReach Biotechnology NonCurrent Deferred Liabilities Related Terms

GeneReach Biotechnology NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for GeneReach Biotechnology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneReach Biotechnology NonCurrent Deferred Liabilities Chart

GeneReach Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GeneReach Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4171
52GF Score
GeneReach Biotechnology Corp ROCO:4171
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of NT$0.0 Mil mean?
GeneReach Biotechnology (ROCO:4171) has a NonCurrent Deferred Liabilities of NT$0.0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GeneReach Biotechnology and its competitors.
Is GeneReach Biotechnology's NonCurrent Deferred Liabilities too high?
GeneReach Biotechnology's current NonCurrent Deferred Liabilities is NT$0.0 Mil. Overall, GeneReach Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's NonCurrent Deferred Liabilities compare to VRTX and REGN?
GeneReach Biotechnology's NonCurrent Deferred Liabilities of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GeneReach Biotechnology and its competitors. GeneReach Biotechnology's current NonCurrent Deferred Liabilities is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.55, compared to a current price of NT$17.20 — trading 29.9% below its estimated fair value. The current NonCurrent Deferred Liabilities is NT$0.0 Mil. GeneReach Biotechnology's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current NonCurrent Deferred Liabilities is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?

Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued. The current stock price of NT$17.20 is trading 29.9% below its estimated GF Value™ of NT$24.55. GuruFocus considers GeneReach Biotechnology to be Possible Value Trap.

Key valuation signals for ROCO:4171:

  • NonCurrent Deferred Liabilities: NT$0.0 Mil
  • GF Value™: NT$24.55 vs. price of NT$17.20 (29.9% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneReach Biotechnology Business Description

Address No.19, Keyuan 2nd Road, Taichung, TWN, 407
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
52GF Score

Get the complete analysis for ROCO:4171

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.20
Price
NT$24.55
GF Value